Personalis, Inc
This is an onsite laboratory role at Personalis supporting the processing and quality oversight of clinical samples used for next-generation sequencing and cancer testing. The position operates in a BSL-2 laboratory environment and contributes to maintaining laboratory compliance, data integrity, and instrument performance during assigned shifts. The role is entry-level and supports continuous improvement within the lab.
Headquarters
Fremont, California, United States
Company Size
201-500 employees
Founded
2011
Personalis is a genomics company transforming the active management of cancer through advanced ctDNA (circulating tumor DNA) technologies. Their solutions enable highly sensitive liquid biopsy testing, supporting applications from molecular residual disease (MRD) detection to therapy selection. Personalis serves oncology-focused customers seeking actionable cancer insights through cutting-edge sequencing and bioinformatics.
Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of "Moderate Buy" from Analysts
1 day ago
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
2 weeks ago
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
1 month ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Personalis, Inc.
With 42% ownership, Personalis, Inc. (NASDAQ:PSNL) has piqued the interest of institutional investors
Sep 18, 2025
DNA Sequencing Technician - Tuesday-Saturday, 6:00 am – 2:30 pm
Eurofins
Research Assistant
Texas A&M University Health Science Center
Research Associate 1
Natera
DNA Sequencing Technician - Tuesday-Saturday, 2:00am-10:30pm
Eurofins
Molecular Biologist
Pilgrim
Molecular Technologist II
Exact Sciences Corporation